High Growth Tech Stocks To Watch In Europe April 2026
As the pan-European STOXX Europe 600 Index shows a positive trend with a weekly gain of 1.91%, driven by corporate earnings and geopolitical developments, investors are closely watching how these factors might influence high-growth sectors such as technology. In this context, identifying strong tech stocks often involves looking for companies that can capitalize on current market dynamics, such as those benefiting from industrial production growth or adapting to economic shifts signaled by the IMF’s revised eurozone growth forecast.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Hacksaw |
24.17% |
25.33% |
★★★★★★ |
|
2CRSI |
25.76% |
65.41% |
★★★★★★ |
|
Archos |
31.61% |
57.94% |
★★★★★★ |
|
Adtraction Group |
4.79% |
101.86% |
★★★★★☆ |
|
Pharma Mar |
16.75% |
29.35% |
★★★★★☆ |
|
Pexip Holding |
10.80% |
21.88% |
★★★★★☆ |
|
Bonesupport Holding |
23.26% |
33.76% |
★★★★★★ |
|
CD Projekt |
32.85% |
28.82% |
★★★★★☆ |
|
SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
|
Comet Holding |
13.02% |
57.14% |
★★★★★☆ |
Let’s uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pharma Mar, S.A. is a biopharmaceutical company engaged in the research, development, production, and commercialization of bio-active principles for oncology across various international markets including Spain, Germany, and the United States with a market cap of €1.63 billion.
Operations: Pharma Mar, S.A. generates revenue primarily through its oncology segment, contributing €221.35 million, while RNA Interference (RNAi) adds a minimal €0.04 million.
Pharma Mar’s recent approval of ZEPZELCA for ES-SCLC in Australia and Singapore, under Project Orbis, marks a significant stride in its global market reach, reflecting its robust R&D capabilities. The company’s earnings surged by 187% last year, with an impressive forecast growth of 29.4% annually over the next three years, outpacing the Spanish market’s 11.5%. This growth is underpinned by a strategic alliance with Globant to enhance cancer drug discovery using AI, boosting efficiency and accuracy in Pharma Mar’s R&D processes. These developments not only underscore Pharma Mar’s potential in high-growth tech but also highlight its innovative approach to addressing critical health challenges through advanced therapeutics and smart collaborations.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Smartoptics Group ASA is a company that offers optical networking solutions and devices across various regions including the Americas, Europe, the Middle East, Africa, and the Asia-Pacific with a market capitalization of NOK4.88 billion.
Operations: Smartoptics Group ASA generates revenue primarily from its Computer Networks segment, amounting to $75.27 million. The company operates across multiple regions, providing optical networking solutions and devices.
Smartoptics Group ASA, a key innovator in optical networking solutions, has demonstrated robust growth with a 22.2% annual increase in revenue and an impressive 39.1% rise in earnings per year, outstripping the Norwegian market’s growth rates of 3.1% and 11.5%, respectively. The company’s strategic deployment of advanced wavelength services up to 400G for Pilot Fiber enhances connectivity across New York’s demanding enterprise sectors, showcasing its capability to meet escalating data traffic needs efficiently. This approach not only leverages Smartoptics’ technological prowess but also aligns with industry shifts towards higher-capacity networks essential for supporting modern digital ecosystems, positioning it well for future expansions.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Dustin Group AB (publ) operates as an online information technology company across Sweden, Finland, Denmark, the Netherlands, Norway, and Belgium with a market capitalization of approximately SEK2.36 billion.
Operations: Dustin Group AB focuses on the online information technology sector, primarily serving the Large Corporate and Public Sector (LCP) segment, which generates SEK15.74 billion in revenue. The company operates in several European countries, including Sweden, Finland, Denmark, the Netherlands, Norway, and Belgium.
Dustin Group has recently shown a promising turnaround, transitioning from a significant net loss of SEK 2,529 million to a net income of SEK 15 million in its latest quarterly report. This improvement is underscored by a slight increase in sales from SEK 5,480 million to SEK 5,481 million year-over-year and an annual revenue growth projected at 3.1%, outpacing the Swedish market’s growth rate of only 0.2%. The strategic executive changes, including the appointment of Monika Gullin as CTO, signal a strengthening focus on technology leadership within the Nordic region. This shift is pivotal as Dustin aims to stabilize its financials and harness higher market growth rates forecasted for the coming years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:PHM OB:SMOP and OM:DUST.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com